Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

JPMorgan Chase & Co (NY:JPM)

228.69 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about JPMorgan Chase & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Robinhood Stock Draws Attention After JPMorgan Upgrade, Price Target Hike: Retail Enthusiasm Soars
According to TheFly, JPMorgan highlighted that Robinhood has "made notable progress in legitimizing its operations" compared to its primary reliance on meme-stock trading three years ago. 
Via Stocktwits
JPMorganChase Survey: Businesses Ring in the New Year with Renewed Optimism
From JPMorgan Chase & Co.
Via Business Wire
Why Teradyne (TER) Stock Is Up Today
Shares of semiconductor testing company Teradyne (NASDAQ:TER) jumped 7.2% in the afternoon session after Northland analysts upgraded the stock's rating from Market Perform (Hold) to Outperform (Buy)... 
Via StockStory
Optimum-MSGN Standoff Could Pressure MSG Networks' Finances: Analyst
JP Morgan analyst David Karnovsky shared views on the impact of the Optimum-MSGN carriage battle on Sphere Entertainment and Madison Square Garden Sports. 
Via Benzinga
Market Whales and Their Recent Bets on JPM Options
Via Benzinga
Acquisition of Kadima Neuropsychiatry Institute for CNS & Psychedelic Research Planned; New Drug Application for Suicidal Depression Treatment: $NRXP
NRx Pharmaceuticals, Inc.: Stock Symbol: NRXP IS Aiming to be the First FDA-Approved Medication to Treat Suicidal DepressionMIAMI - Jan. 2, 2025 - PRLog -- Developing NRX-101, an FDA-Designated... 
Via PRLog
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Spotlight on JPMorgan Chase: Analyzing the Surge in Options Activity
Via Benzinga
New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects 13+ Million Americans Each Year: NRx Pharma: Stock Symbol:NRXP
$NRXP: Completion of NDA Filing Expected in First Quarter of 2025MIAMI - Dec. 30, 2024 - PRLog -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal... 
Via PRLog
Exposures Product Safety
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
JPMorgan Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
Alphabet Drives Into 2025: Google's AI, Waymo Lead The Charge
Wall Street anticipates Alphabet's Google to continue its innovation streak in 2025, with key growth drivers including generative AI and autonomous driving. JPMorgan analyst reiterates Overweight... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced... 
Via TheNewswire.com
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences
Via Investor Brand Network
Here's How Trump Could Wipe Out 40% of Tesla's Profits After Taking Office, According To JPMorgan Analyst
The profitability of Tesla Inc. could be severely impacted under the second Trump administration, with a potential 40% decrease. 
Via Benzinga
Topics Government
Exposures Political
3 ETFs I'm Buying in January 2025
Via The Motley Fool
Topics ETFs
A Mass Exodus Of Big Banks From The Net-Zero Bank Climate Alliance
Citigroup, BofA, and Morgan Stanley join Vanguard, JPMorgan, BlackRock, State Street, Goldman Sachs and Wells Fargo in leaving. 
Via Talk Markets
Q4 Earnings Season Looms: A Preview
The expectation is that 2024 Q4 earnings for the S&P 500 index will be up +7.6% on +4.7% higher revenues. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
3 Top Value Stocks to Buy in January
This year could look dramatically different than the past few have. Start it on the right foot with these three underestimated prospects. 
Via The Motley Fool
Ranked: The World’s Top Companies By Revenue In 2024
Today, U.S. retail giants are the largest companies by revenue globally thanks to their international reach and the strength of the American consumer. 
Via Talk Markets
The question on everyone's mind: Will JPMORGAN CHASE & CO breakout?
The technical analysis for JPMORGAN CHASE & CO (NYSE:JPM) is highly positive, with a rating of 9 out of 10, suggesting a potential breakout. 
Via Chartmill
Under the Radar: New Year, New Financial Frontiers -Beyond the Big Banks
Via Benzinga
3 Stocks Helping to Bring AI to Healthcare
Many profitable companies are using AI to make healthcare more efficient; and these companies are rewarding investors with share price growth and dividends 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead. 
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
Dow Jones 2024 Scoreboard: Top 5 Winners, Losers — And How Amazon, Nvidia Could Reshape 2025
Several of the worst performing 2024 Dow Jones stocks won't be included in returns in 2025. A look at the best and worst performers and what's ahead. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Earnings Set to Shine: January's Critical Market Test
The analysts expect S&P 500 earnings growth to accelerate in Q4 and be led by the financials, including JPMorgan Chase & Company. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
'Zelle Became A Gold Mine For Fraudsters': Consumer Financial Protection Bureau Lawsuit
Last week, the Consumer Financial Protection Bureau sued 3 of the nation's largest banks and the operator of Zelle for failing to protect consumers from widespread fraud on the peer-to-peer payment... 
Via Benzinga
Topics Fraud Lawsuit
Exposures Financial Legal
Banks And Business Groups Challenge Fed's Stress Test Rules
Major US banks sue Federal Reserve over lack of transparency in stress testing, claiming opaque processes create volatile capital requirements. 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Year of Concentration, Crypto, China
2024 was another stellar year for investors, but a lot of money is piling into the same places in the U.S. and globally. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.